- Questions this article answers
- How long does Thermage last?
- What is Solta Medical Corporation?
- Is Solta Medical stock publicly traded?
- Can Thermage and Fraxel improve skin tone and texture?
- What does a Solta Medical device actually cost to own?
- How should a clinic evaluate Thermage and Fraxel claims?
- What question do most clinics forget to ask?
If you're evaluating Solta Medical's Thermage or Fraxel platforms, you're probably juggling three lists: one from clinicians, one from procurement, and one from patients. This article answers the questions that show up on all three—plus one or two that nobody puts on a list but should.
Quick context: I'm a quality and brand compliance manager in the medical aesthetics device space. I review roughly 200 marketing claims and equipment specs every year before they reach customers. In 2024, I rejected about 15% of first drafts for unsupported claims. The questions below are the ones I keep coming back to.
Questions this article answers
- How long does Thermage last?
- What is Solta Medical Corporation?
- Is Solta Medical stock publicly traded?
- Can Thermage and Fraxel improve skin tone and texture?
- What does a Solta Medical device actually cost to own?
- How should a clinic evaluate Thermage and Fraxel claims?
- What question do most clinics forget to ask?
How long does Thermage last?
The short answer: 12 to 18 months for most patients, with some published reports showing measurable effects up to two years.
Thermage uses monopolar radiofrequency to heat the dermis and trigger collagen contraction and remodeling. New collagen takes time to organize—usually three to six months before the full result becomes visible. After that, the tightening effect gradually fades as normal aging resumes. Most clinics schedule touch-ups at 12- to 18-month intervals.
Two things influence longevity: baseline skin condition and treatment protocol. Patients with mild-to-moderate laxity generally see longer-lasting results than patients with advanced aging. And a conservative energy protocol produces a different durability profile than an aggressive one.
From a compliance perspective, we coach clinics to document the protocol used and the patient's baseline, so longevity expectations are grounded in something measurable.
I check one thing in every claim review: whether the "how long does Thermage last" question is answered honestly. Language implying permanent results isn't just a customer-service failure—it's a compliance risk.
What is Solta Medical Corporation?
Solta Medical is the manufacturer behind three widely used platforms in medical aesthetics: Thermage for monopolar radiofrequency skin tightening, Fraxel for non-ablative fractional laser texture and tone work, and Clear + Brilliant for lower-dose maintenance treatments.
The company's roots go back to the early 2000s, when Thermage received its first FDA clearance. Fraxel followed, and together the platforms gave clinics a non-invasive option for patients who wanted visible improvement without surgical downtime.
The multi-technology portfolio is the strategic point: a clinic can offer both RF-based tightening and laser-based resurfacing without maintaining relationships with multiple manufacturers.
One point regularly confuses buyers: Solta Medical hasn't been an independent company since January 2014, when Bausch Health—then Valeant Pharmaceuticals—acquired it. The brand lives on for the device lines, but corporate-level reporting now sits inside Bausch Health.
Is Solta Medical stock publicly traded?
Not as an independent equity. If you search "solta medical stock" and find tickers labeled SOLTA, those track a company that stopped existing in standalone form in January 2014, when Valeant completed its approximately $250 million cash acquisition of Solta Medical.
Valeant later rebranded as Bausch Health Companies. Current financial filings—10-Ks, quarterly reports, investor presentations—are published under Bausch Health (NYSE: BHC).
If a broker mentioned "Solta Medical stock" in a pitch, the math is simple: the company's equity has been part of a much larger balance sheet for over a decade. Retail advice built around a standalone Solta ticker isn't current.
Why should a clinic care? Equipment purchases involve a "will the manufacturer still support this in five years?" question. Bausch Health is a large corporation, but portfolio shifts happen. And when procurement validates vendor stability, they're really validating service-contract longevity. A device is only as good as the calibration, replacement tips, and technical support behind it.
Can Thermage and Fraxel improve skin tone and texture?
Yes—but the mechanism deserves more attention than the marketing phrase.
Fraxel creates microthermal zones: thousands of small columns of controlled thermal injury. They trigger a repair cascade. Damaged pigmentation is shed, fresh keratinocytes migrate in, and dermal collagen is stimulated. That's the skin tone evening treatment effect. The collagen response is also what improves texture and refines pores over time.
Thermage works at a deeper structural level. Monopolar RF heats the dermis, contracting existing collagen and driving new collagen formation over the following months. That's why the two are often combined: Fraxel manages the surface, Thermage manages the support structure.
The caveat: results are gradual. The meaningful outcome window is 8–12 weeks, not 48 hours. Combination protocols are increasingly common, but each modality still carries its own candidate profile and recovery pattern—and that belongs in the informed consent.
What does a Solta Medical device actually cost to own?
The sticker price is the least interesting number in the procurement file. It took me four years and roughly 60 equipment evaluations to understand that.
Total cost of ownership includes the acquisition cost; consumables like Thermage treatment tips and Fraxel tips, which are single-use and recur at $300+ per treatment; service and calibration contracts, which matter especially for RF devices because calibration drift affects both safety and outcomes; staff training; patient education; and room time.
Run the per-treatment math. An $80,000 device with those consumables works at 50 treatments a month. At 10 a month, it probably doesn't. Financing changes the picture too—a lease looks simpler, but interest can add 20–30% over five years.
Service contracts are negotiable, by the way. In 2025, we've seen everything from 10% discounts for annual prepayment to bundled calibration visits. The published price is a starting point, not a fixed ceiling.
That said, my experience is based on mid-sized clinic evaluations. A single-provider practice faces different economics, and fixed costs hit harder at low volume.
How should a clinic evaluate Thermage and Fraxel claims?
Start with the FDA clearance letter, not the sales brochure. (This one's worth repeating.)
510(k) clearance means a device is substantially equivalent to a predicate device. It does not mean the FDA independently validated every marketing claim. And clearance is not approval—PMA approval is a different, far more demanding pathway that most aesthetic devices don't go through.
When a representative says "FDA approved," ask for the clearance number. Look it up in the FDA's 510(k) database. Read the cleared indications. A device cleared for "wrinkle reduction" is not automatically cleared for "skin tightening," even if both phrases appear on the same landing page.
The same discipline applies to clinical studies. Look at what was measured: standardized photography, blinded evaluator grading, validated scales. Check the follow-up period. Laser texture improvement and tone-evening effects take months to develop; a two-month study misses most of the story.
I learned this through a 2023 audit. We found a consent form that repeated language unsupported by the clearance—it had been in use for nine months. The fix wasn't just rewriting the form. It was building a verification step into every new claim.
What question do most clinics forget to ask?
"What happens when the handpiece fails calibration right before a patient arrives?"
The tip is single-use. The device flags it as out of range. The patient is prepped and waiting. Your clinic has two choices: discard the tip and reschedule—lost revenue plus an unhappy patient—or run the treatment anyway and accept the risk.
That's a risk management issue, not a facility issue. I now negotiate service contracts for devices like Thermage and Fraxel with three questions:
- What's the expected failure rate for tips and handpieces?
- What does an out-of-warranty replacement cost?
- What's the service response time if the device goes down?
The third question is the expensive one to ignore. A device down for six weeks generates no revenue. In aesthetics, patients expect availability. Every week of downtime costs more than the repair bill. And don't just accept a verbal estimate—ask for the response time in writing. We had a contract that promised "48-hour response," which turned out to be an estimate, not a guarantee. That difference cost us two weeks of downtime.
